Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Gordon Davis

Showing results (11-20 of 14) with videos related to

Pageof 2
Sort By:
You have reached the last page of results.This site can display upto 14 results.
Circulation. Genomic and Precision Medicine|October 26, 2018
Dose Response of β-Blockers in Adrenergic Receptor Polymorphism GenotypesKishan S Parikh, Mona Fiuzat, Gordon Davis, et al.
European Journal of Heart Failure|December 11, 2012
Effect of bucindolol on heart failure outcomes and heart rate response in patients with reduced ejection fraction heart failure and atrial fibrillationDavid P Kao, Gordon Davis, Ryan Aleong, et al.
Plos One|October 17, 2012
Combinatorial pharmacogenetic interactions of bucindolol and β1, α2C adrenergic receptor polymorphismsChristopher M O'Connor, Mona Fiuzat, Peter E Carson, et al.
JACC. Heart Failure|May 3, 2019
Bucindolol for the Maintenance of Sinus Rhythm in a Genotype-Defined HF Population: The GENETIC-AF TrialJonathan P Piccini, William T Abraham, Christopher Dufton, et al.
Pageof 2

Showing results (11-20 of 14) with videos related to

Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 14 results.
Circulation. Genomic and Precision Medicine|October 26, 2018
Dose Response of β-Blockers in Adrenergic Receptor Polymorphism GenotypesKishan S Parikh, Mona Fiuzat, Gordon Davis, et al.
European Journal of Heart Failure|December 11, 2012
Effect of bucindolol on heart failure outcomes and heart rate response in patients with reduced ejection fraction heart failure and atrial fibrillationDavid P Kao, Gordon Davis, Ryan Aleong, et al.
Plos One|October 17, 2012
Combinatorial pharmacogenetic interactions of bucindolol and β1, α2C adrenergic receptor polymorphismsChristopher M O'Connor, Mona Fiuzat, Peter E Carson, et al.
JACC. Heart Failure|May 3, 2019
Bucindolol for the Maintenance of Sinus Rhythm in a Genotype-Defined HF Population: The GENETIC-AF TrialJonathan P Piccini, William T Abraham, Christopher Dufton, et al.
Pageof 2